Mannkind Corporation (NASDAQ:MNKD) Grows Big On Sanofi


Dallas, Texas 08/29/2014 (FINANCIALSTRENDS) – MannKind Corporation (NASDAQ:MNKD) the bio sector player has definitely set the ball rolling on a positive note, thanks to the new deal it has announced via Sanofi.

The question now is how this will affect the prices of this bio sector player. The tie-up with Sanofi offers exceptional scope for the share prices of Mannkind to see a price rise from current prices of $6.50 into two-digit figures in the following quarters.

But investors and analysts predict that MannKind Corporation (NASDAQ:MNKD) will see massive growth if this stock is held for over a longer period of 3 years over short term.

The company following the announcement of its current deal with Sanofi, has resulted in the $125 million payment as the first step. The company will continue to receive milestone payments for the additional $800 million payment. Therefore, as Sanofi sells Afrezza, it gains the right as well as license offering a 65:35 between Mannkind and Sanofi respectively.

For Sanofi is the gains are in the leveraging the sale of one of the largest drugs seen in over a decade. For Mannkind the gains are in Sanofi’s expertise as a business which has succeeded as a pharma startup.

MannKind Corporation (NASDAQ:MNKD) will continue to see marked profits and share price rise for the unique product it has in Afreeza.

For now as diabetes, the lifestyle disease, spreads like wild fire not only in continental North America but in Asia as well, the sheer market size is staggering for breakthrough drugs such as Afreeza.

Diabetes treatments are evolving and the move to the next level with inhaled insulin has definitely set the standards of delivery of treatment high for this disease currently in the US.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.